Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) on Tuesday, plunged -1.75% from the previous trading day, before settling in for the closing price of $23.45. Within the past 52 weeks, CPRX’s price has moved between $12.43 and $24.27.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 4106.79%. The company achieved an average annual earnings per share of 88.89%. With a float of $102.94 million, this company’s outstanding shares have now reached $107.12 million.
The extent of productivity of a business whose workforce counts for 167 workers is very important to gauge. In terms of profitability, gross margin is 82.23%, operating margin of 37.97%, and the pretax margin is 41.2%.
Catalyst Pharmaceuticals Inc (CPRX) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Catalyst Pharmaceuticals Inc is 13.70%, while institutional ownership is 75.56%. The most recent insider transaction that took place on Nov 12 ’24, was worth 1,620,856. Before that another transaction happened on Nov 12 ’24, when Company’s Director proposed sale 192,000 for $23.30, making the entire transaction worth $4,473,224.
Catalyst Pharmaceuticals Inc (CPRX) Performance Highlights and Predictions
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported 0.31 earnings per share (EPS) for the period topping the consensus outlook (set at 0.26) by 0.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.29 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 88.89% per share during the next fiscal year.
Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) Trading Performance Indicators
Catalyst Pharmaceuticals Inc (CPRX) is currently performing well based on its current performance indicators. A quick ratio of 4.92 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.97. Likewise, its price to free cash flow for the trailing twelve months is 14.62.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 1.17, a number that is poised to hit 0.32 in the next quarter and is forecasted to reach 1.51 in one year’s time.
Technical Analysis of Catalyst Pharmaceuticals Inc (CPRX)
The latest stats from [Catalyst Pharmaceuticals Inc, CPRX] show that its last 5-days average volume of 1.64 million was superior to 1.2 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 74.05%. Additionally, its Average True Range was 0.73.
During the past 100 days, Catalyst Pharmaceuticals Inc’s (CPRX) raw stochastic average was set at 87.08%, which indicates a significant increase from 61.08% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 25.05% in the past 14 days, which was lower than the 35.40% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $20.87, while its 200-day Moving Average is $17.31. Now, the first resistance to watch is $23.52. This is followed by the second major resistance level at $23.99. The third major resistance level sits at $24.26. If the price goes on to break the first support level at $22.78, it is likely to go to the next support level at $22.51. Assuming the price breaks the second support level, the third support level stands at $22.04.
Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) Key Stats
Market capitalization of the company is 2.75 billion based on 119,273K outstanding shares. Right now, sales total 398,200 K and income totals 71,410 K. The company made 128,700 K in profit during its latest quarter, and 43,880 K in sales during its previous quarter.
